Journal
SUPPORTIVE CARE IN CANCER
Volume 31, Issue 12, Pages -Publisher
SPRINGER
DOI: 10.1007/s00520-023-08069-8
Keywords
Inflammation; Inflammatory cytokines; Medicinal cannabis; Advanced cancer
Ask authors/readers for more resources
This study aimed to investigate the anti-inflammatory effect of cannabidiol (CBD) in cancer patients by measuring the levels of serial C-reactive protein (CRP) and inflammatory cytokines. However, the results showed no significant difference in the trajectory of CRP or cytokine levels between the CBD and placebo groups.
PurposeInflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.MethodSerial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.ResultsThere was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.ConclusionWe were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.Trial registrationANZCTR 26180001220257, registered 20/07/2018.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
